Topical nanocarriers for management of Rheumatoid Arthritis: A review

Chando, Anita; Momin, Munira; Quadros, Mural; Shaily, Lalka

doi:10.1016/j.biopha.2021.111880

Cited by 64 publications

(32 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the same time, the balance of the large-scale system is compelled to be dealt with. Generally, the balanced surface modification density is the decisive element to attain the fantastic targeting ability [ 129 , 142 , 143 ]. Moreover, despite the ginormous benefits and potential of the aforementioned systems, they tend to be overly complex, and many remain just proof-of-concept.…”

Section: Challenges and Prospective Of Stimuli-responsive Nano-drug D...mentioning

confidence: 99%

Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment

Zhang

Cai

et al. 2022

Materials Today Bio

152

View full text Add to dashboard Cite

Section: Challenges and Prospective Of Stimuli-responsive Nano-drug D...mentioning

confidence: 99%

Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment

Zhang

Cai

et al. 2022

Materials Today Bio

152

View full text Add to dashboard Cite

“…Transferosomes are found to improve the stability and the efficacy of anti-inflammatory drugs. Transferosomes embedded with curcumin were developed and have shown an increase in their permeation capability and bioavailability ( Anita et al, 2021 ). A study on the antiarthritic activity of capsaicin-loaded transferosomes in arthritic rats showed better inhibitory activity and the desired therapeutic concentration of the drug at the target site ( Jain et al, 2021 ).…”

Section: Phytochemical Delivery Through Transferosome (Phytosome)mentioning

confidence: 99%

Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines

et al. 2022

View full text Add to dashboard Cite

Transdermal drug delivery aims to create a safe and effective method of administering drugs through the skin that attracts a lot of attention and investment due to the constant progress in the field. Transferosomes are flexible or malleable vesicles (having almost the same structure as liposomes but with better skin penetration properties) discovered initially in the early 90s. The name transferosomes, which means “carrying bodies,” is coined from the Latin phrase “Transferee,” which means “to carry through,” and the Greek term “soma,” meaning “body.” In comparison to typical herbal extracts, phytosomes (Transferosomes) are created by attaching specific herbal extracts to phosphatidylcholine, resulting in a formulation with increased solubility and, hence, better absorption, resulting in improved pharmacokinetic and pharmacodynamic features of the entrapped drugs. We are using the word phytosomes and transferosomes interchangeably as we have consolidated vesicular delivery of herbal drugs through skin. In this mini-review, we have demonstrated the enormous potential of developing nanotechnology to deliver bioactive phytochemicals, with a special emphasis on phytosomes (Transferosomes) as a unique lipid-based nanocarrier for transdermal drug delivery.

show abstract

“…Integrating knowledge of NR4A1-3 modulation and the impact on cell-and tissue-specific functional activities, at distinct stages during chronic inflammation, will facilitate the development of new therapeutic targets and strategies. To complement progression in the potential application of NR4A ligands as viable therapeutic options are recent developments in drug delivery systems (109). For example in the field of nanomedicine, the development of precision nanocarriers, which can be modified to enable site-and cell-specific delivery, have been loaded with therapeutic agents, including steroids, are showing improved permeability and retention in the joint space, with enhanced bioavailability and bioactivity, and reduced clearance rates (110,111).…”

Section: Nr a -Receptors And Emerging Therapeutic Strategies In Rheum...mentioning

confidence: 99%

“…For example in the field of nanomedicine, the development of precision nanocarriers, which can be modified to enable site-and cell-specific delivery, have been loaded with therapeutic agents, including steroids, are showing improved permeability and retention in the joint space, with enhanced bioavailability and bioactivity, and reduced clearance rates (110,111). Furthermore, such advances can augment drug efficacy and reduce unwanted systemic adverse effects (109).…”

Section: Nr a -Receptors And Emerging Therapeutic Strategies In Rheum...mentioning

confidence: 99%

NR4A1-3 nuclear receptor activity and immune cell dysregulation in rheumatic diseases

Murphy

Crean

2022

Front. Med.

View full text Add to dashboard Cite

The development and progression of immune-mediated rheumatic disease (IMRD) involves dysfunction of innate and adaptive immune cell populations leading to altered responses including inflammasome activation, dysregulated cytokine networks, increased immune cell numbers and multifaceted cell-cell communication. Several rheumatic diseases are further characterized by the presence of autoantibodies, immune complex mediated complement activation and the deficit of peripheral immune tolerance due to reduced regulatory T-lymphocyte cell function. Ultimately, in rheumatic disease the loss in cellular and tissue homeostasis culminates in the advancement of chronic inflammation. The three members of the NR4A subfamily of nuclear receptors are immediate early genes, and act as potent transcriptional responders to changes in the cellular and tissue microenvironment. Subfamily members are rapidly expressed in diseases characterized by inflammation and function to control the differentiation and activity of innate and adaptive immune cells in a cell-type and cell-context specific manner. Rheumatic disease including rheumatoid-, psoriatic-, osteo-arthritis and systemic sclerosis display altered NR4A1-3 activity in controlling immune cell migration and function, production of paracrine signaling molecules, synovial tissue hyperplasia, and regulating cartilage turn-over in vivo. Additionally, NR4A1-3 activities mediate cytokine, prostanoid and growth factor signaling to control angiogenesis, modulate the regulatory functions of mesenchymal stromal cells, alter the activation status of dendritic cells, influence the generation of peripheral myeloid and T-lymphocyte lineages and promote the maintenance of functional regulatory T-cells. Further reports uncover the potential of moderating NR4A 1-3 receptors as therapeutic targets in altering immune tolerance, pathological angiogenesis and controlling inflammation in several models of disease.

show abstract

Topical nanocarriers for management of Rheumatoid Arthritis: A review

Cited by 64 publications

References 149 publications

Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment

Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment

Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines

NR4A1-3 nuclear receptor activity and immune cell dysregulation in rheumatic diseases

Contact Info

Product

Resources

About